This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Monday, December 17, 2012
HCV Transplant Studies GS-7977 Also Telaprevir & Boceprevir
New From NATAP
Telaprevir & Boceprevir in Liver Transplantation
Telaprevir therapy required tacrolimus dose reduction in liver transplant recipients with HCV -
GS-7977 HCV Transplant Studies
Telaprevir Post Liver Transplant
Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data
Boceprevir HCV Liver Transplant
No comments:
Post a Comment